Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer

✍ Scribed by Bassel F. El-Rayes; Mark M. Zalupski; Stephanie G. Manza; Barbara Rusin; Ann Marie Ferris; Ulka Vaishampayan; Lance K. Heilbrun; Raghu Venkatramanamoorthy; Anthony F. Shields; Philip A. Philip

• Publisher: Springer
• Year: 2007
• Tongue: English
• Weight: 304 KB
• Volume: 61
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-007-0472-1